T-cell engagers to drive immuno-oncology next growth wave: GlobalData
Bispecific T-cell engagers forecast to expand from 10% to 35% of the global immuno-oncology market by 2031 as immune checkpoint…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
cancer immunotherapy
IGI reports phase 1 results of ISB 2001 trispecific antibody in relapsed or refractory multiple…
TRIgnite-1 study shows 79 per cent response rate and no dose-limiting toxicities in early-stage trial of BCMA × CD38 × CD3…
New cancer immunotherapy fails in first Roche trial
The Skyscraper-II trial was the first to produce results in the final stage of clinical testing in a class of drugs known as…
US FDA approves new Bristol Myers cancer immunotherapy
The company said it expects the treatment to eventually garner annual sales of more than $4 billion
US FDA grants priority review to Roche’s Tecentriq as adjuvant treatment for non-small cell lung…
Tecentriq is the first and only cancer immunotherapy to demonstrate positive phase-III results in the adjuvant lung cancer setting…
Roche gets US FDA approval for Tecentriq combo to treat advanced melanoma
The approval is based on results from the Phase III IMspire150 study, in which the addition of Tecentriq to Cotellic and Zelboraf…
DBT invites LoI to set up Virtual Network Centers in cancer immunology and immunotherapy
Calls on scientists and researchers to create a centralised platform and work together to develop and actualise a cancer research…
Bristol Myers says Opdivo performs well in kidney, lung cancer trials
Opdivo is one of Bristol’s top-selling drugs, but sales of the drug have slowed in recent years as it has been eclipsed by Merck…
Virtual Bio Pharma Conclave 2020 – Accelerating Biopharma Innovation | 21st April 2020
Recent Advancement In Cancer Immunotherapy And Novel CAR-T Development ~ Tue, Apr 21, 2020 | 3:00 PM - 4:00 PM IST